This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 9
  • /
  • Japanese MHLW approves Ezharmia for relapsed or re...
News

Japanese MHLW approves Ezharmia for relapsed or refractory adult T-cell leukemia/lymphoma

Read time: 1 mins
Published:28th Sep 2022

Daiichi Sankyo announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Ezharmia (valemetostat tosilate), a first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL)

Ezharmia previously received Orphan Drug Designation (ODD) from the MHLW for this indication and is now the first dual inhibitor of EZH1 and EZH2 to be approved for treatment of ATL. A rare and aggressive hematologic malignancy that can manifest as either leukemia or lymphoma, ATL occurs with higher frequency in certain regions of Japan and is associated with a five-year overall survival rate of approximately 14%.

The approval of Ezharmia by the MHLW is based on results of an open-label, single-arm pivotal phase II study evaluating efficacy and safety in 25 patients with three aggressive subtypes of relapsed or refractory ATL in Japan. The study demonstrated an objective response rate (ORR) of 48% (95% CI: 27.8%-68.7%), as evaluated by an independent efficacy assessment committee. Complete responses (CR) were seen in 20% of patients (n=5) and partial responses (PR) in 28% of patients (n=7).

Ezharmia was generally well-tolerated in the phase II study. Drug-related treatment emergent adverse events occurred in 24 of 25 patients (96%) with the most common including platelet count decrease (80%), anemia (44%), alopecia (40%), dysgeusia (36%), lymphocyte count decrease (20%), neutrophil count decrease (20%) and white blood cell count decrease (20%).

Condition: T- cell Leukemia/Lymphoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.